Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Baseline Characteristics of Participants in the Final Analysis, by Hepatitis C Status Characteristic | Participants With HCV (n = 40) | Participants Without HCV (n = 48) | P Value: Vitamin D supplement use | 8 (20.0) | 13 (27.1) | .438
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
We conducted a cohort study of 40 participants who initiated DAAs and achieved cure and 48 without HCV as controls.
Source: Abstract.
Participants were recruited from 1 January 2019 through 31 July 2022.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Changes in Bone Microarchitecture and Inflammatory Cytokines After Cure of Chronic Hepatitis C Infection With Direct-Acting Antiviral Therapy
Cohort study · Open Forum Infectious Diseases · 2025
Original publication title
Changes in Bone Microarchitecture and Inflammatory Cytokines After Cure of Chronic Hepatitis C Infection With Direct-Acting Antiviral Therapy
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
It remains unclear if cure of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) ameliorates HCV-related inflammation and bone deficits. We evaluated changes in cytokines and bone measurements by high-resolution peripheral quantitative computed tomography (HR-pQCT) prior to DAA treatment and 18 months following initiation and compared changes in uninfected controls over 18 months.
Source: BackgroundAbstract: What methods does the paper describe?
We conducted a cohort study of 40 participants who initiated DAAs and achieved cure and 48 without HCV as controls. At enrollment and 18 months later, participants had measurements of volumetric bone mineral density, cortical dimensions, and mechanical properties of the radius and tibia by HR-pQCT; visceral fat area and appendicular lean mass by whole-body dual-energy X-ray absorptiometry; and serum tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interleukin 18 (IL-18). Multivariable linear regression was used to estimate group differences in mean changes in bone measurements and cytokines.
Source: MethodsAbstract: Results
We observed no significant differences in month 0 to 18 changes in HR-pQCT measurements between participants with cured HCV and controls in unadjusted models or after adjustment for age, sex, appendicular lean mass index, visceral fat area, and smoking. Participants with cured HCV had decreases in IL-18 (mean change, −0.085 vs +0.086 log pg/mL; P < .001) and TNF-α (mean change, −0.050 vs +0.084 log pg/mL; P < .001), but not IL-6 (mean change, +0.108 vs +0.009 log pg/mL; P = .214) versus controls.
Source: ResultsAbstract: Conclusions
Participants with cured HCV had no significant changes in bone microarchitecture by HR-pQCT 18 months after DAA initiation compared with controls, but did have decreases in IL-18 and TNF-α versus controls.
Source: ConclusionsAuthors’ abstract
Abstract
Background
It remains unclear if cure of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) ameliorates HCV-related inflammation and bone deficits. We evaluated changes in cytokines and bone measurements by high-resolution peripheral quantitative computed tomography (HR-pQCT) prior to DAA treatment and 18 months following initiation and compared changes in uninfected controls over 18 months.
Methods
We conducted a cohort study of 40 participants who initiated DAAs and achieved cure and 48 without HCV as controls. At enrollment and 18 months later, participants had measurements of volumetric bone mineral density, cortical dimensions, and mechanical properties of the radius and tibia by HR-pQCT; visceral fat area and appendicular lean mass by whole-body dual-energy X-ray absorptiometry; and serum tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and interleukin 18 (IL-18). Multivariable linear regression was used to estimate group differences in mean changes in bone measurements and cytokines.
Results
We observed no significant differences in month 0 to 18 changes in HR-pQCT measurements between participants with cured HCV and controls in unadjusted models or after adjustment for age, sex, appendicular lean mass index, visceral fat area, and smoking. Participants with cured HCV had decreases in IL-18 (mean change, −0.085 vs +0.086 log pg/mL; P < .001) and TNF-α (mean change, −0.050 vs +0.084 log pg/mL; P < .001), but not IL-6 (mean change, +0.108 vs +0.009 log pg/mL; P = .214) versus controls.
Conclusions
Participants with cured HCV had no significant changes in bone microarchitecture by HR-pQCT 18 months after DAA initiation compared with controls, but did have decreases in IL-18 and TNF-α versus controls.
Publication and source details
Original title: Changes in Bone Microarchitecture and Inflammatory Cytokines After Cure of Chronic Hepatitis C Infection With Direct-Acting Antiviral Therapy
Vincent Lo Re III; Dean M Carbonari; Craig W Newcomb; Jessie Torgersen; Erica J Weinstein; Shanae M Smith; Katherine L Brecker; X Sherry Liu; Jay R Kostman; Stacey Trooskin; Rebecca A Hubbard; Joshua F Baker; Babette S Zemel; Mary B Leonard
Open Forum Infectious Diseases · 2025
Correspondence: Vincent Lo Re III, MD, MSCE, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 836 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021 (vincentl@pennmedicine.upenn.edu); Jessie Torgersen, MD, MSCE, Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3801 Filbert Street, Suite 103, Philadelphia, PA 19104 (jessie.torgersen@pennmedicine.upenn.edu).Potential conflicts of interest. The authors: No reported conflicts of interest.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T02:58:08.174413+00:00
DOI: 10.1093/ofid/ofaf571 · PMC12465109